<i>Journal of Gastroenterology and Hepatology</i>｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma

doi:10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5

Volume 38 Issue 2

Feb. 2022

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(2): 401-401

PDF( 871 KB)

Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5

Published Date: 2022-02-20

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Journal of Hepatology｜Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1537-1537. doi: 10.12449/JCH2408.gwqkjpwzjj1
[2]	Journal of the American Medical Association｜Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1652-1652. doi: 10.12449/JCH2408.gwqkjpwzjj3
[3]	Hong NIE, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(8): 1620-1626. doi: 10.12449/JCH240818
[4]	Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy[J]. Journal of Clinical Hepatology, 2024, 40(11): 2237-2237. doi: 10.12449/JCH2411.gwqkjpwzjj2
[5]	Kangjie YANG, Yongliang LU, Weijian E. Immune escape of hepatic echinococcosis based on the PD-1/PD-L1 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(1): 218-225. doi: 10.3969/j.issn.1001-5256.2023.01.034
[6]	Hepatology International｜Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial[J]. Journal of Clinical Hepatology, 2023, 39(10): 2431-2431. doi: 10.3969/j.issn.1001-5256.2023.10.gwjpwzjj1
[7]	Journal of Gastroenterology and Hepatology｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis[J]. Journal of Clinical Hepatology, 2023, 39(11): 2523-2523. doi: 10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1
[8]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[9]	Journal of Hepatology｜Single-cell RNA sequencing reveals the presence of an MDK-dependent immunosuppressive microenvironment in ErbB pathway-mutated gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 281-281. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj1
[10]	Journal of Gastroenterology and Hepatology｜A high serum ferritin level increases the risk of death associated with chronic liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(2): 438-438. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj9
[11]	Hepatology｜Lenvatinib exerts a therapeutic effect on hepatocellular carcinoma by targeting fibroblast growth factor receptor 4 to reduce PD-1[J]. Journal of Clinical Hepatology, 2022, 38(2): 435-435. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj8
[12]	Journal of Hepatology｜PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(3): 698-698. doi: 10.3969/j.issn.1001-5256.2022.3.gwjpwzjj2
[13]	Ran CHENG, Xiaoyuan XU. Efficacy and safety of programmed death-1/programmed death-ligand 1 inhibitors in treatment of hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2160-2164. doi: 10.3969/j.issn.1001-5256.2022.09.041
[14]	Journal of Gastroenterology and Hepatology｜Rifampicin can improve cholestasis in patients with persistent hepatocellular secretory failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 396-396. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj4
[15]	Journal of Clinical Oncology｜Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial[J]. Journal of Clinical Hepatology, 2022, 38(10): 2312-2312. doi: 10.3969/j.issn.1001-5256.2022.10.gwjpwzjj3
[16]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[17]	Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020
[18]	Ha FuShuang, Han Tao, Tang Fei, Yan JunQing, Wang HaoYu. Predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1389-1392. doi: 10.3969/j.issn.1001-5256.2020.06.044
[19]	Pan SiYu, Wang ZhiXin, ZHOU Ying, Wang Tao, Yin Jie, Wang Qiang, Fan HaiNing. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(3): 672-676. doi: 10.3969/j.issn.1001-5256.2019.03.050
[20]	Tao LiLin, Lai Xin, Wei Jia. PD-1/PD-L signaling pathway in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(12): 2373-2378. doi: 10.3969/j.issn.1001-5256.2016.12.031

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	刘松，张永会，王庆东，李龙，于广计. 经导管肝动脉持续灌注治疗序贯卡培他滨及PD-1抑制剂治疗不可切除肝门部胆管癌的疗效及安全性. 中国癌症防治杂志. 2024(01): 90-95 .
2.	陈艳妮，张建红，李健，李瑶，逯震芳，陈亮. PD-1抑制剂联合一线化疗方案对晚期驱动基因阴性肺腺癌的效果及安全性分析. 河北医药. 2024(08): 1184-1187 .
3.	黄健华，张云雷. 信迪利单抗联合XELOX方案在结直肠癌患者中的应用. 河北医药. 2024(08): 1210-1213 .
4.	邓建华，赵新华. 帕博利珠单抗联合化疗治疗晚期肝内胆管细胞癌的效果及对肿瘤标志物的影响. 中国医学创新. 2023(16): 1-4 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (293) PDF downloads(34)

Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5

References

Relative Articles

Cited by

Periodical cited type(4)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5

References

Relative Articles

Cited by

Periodical cited type(4)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content